In mammalian cells, the aurora kinases (aurora-A, -B, and -C) play essential roles in regulating cell division. Aurora-A and -B expression is elevated in a variety of human cancers and is associated with high proliferation rates and poor prognosis, making them attractive targets for anticancer therapy. AMG 900 is an orally bioavailable, potent and highly selective pan-aurora kinase inhibitor that is active in taxane-resistant tumor cell lines. In tumor cells, AMG 900 inhibited autophosphorylation of aurora-A and -B as well as phosphorylation of histone H3 on Ser 10
Introduction
Somatic cell division is a complex and highly coordinated process that ensures faithful segregation of duplicated chromosomes into two daughter cells. Deregulation of the cell cycle is a hallmark of cancer, characterized by uncontrolled proliferation and defects in chromosome segregation.
Antimitotic drugs that block tumor cell division are a proven intervention strategy in the treatment of cancer. However, the clinical benefits of classical antimitotic drugs may be hampered by development of multidrug resistance (MDR) and collateral damage to non-dividing cells including for example, peripheral neuropathy (1) . Aurora kinases are essential mitotic regulators and their potential role in tumorigenesis makes them attractive targets for anticancer therapy (2) (3) (4) .
In mammalian cells, the aurora family of serine/threonine protein kinases is comprised of three paralogous genes (aurora-A, -B, and -C). Aurora-A and -B are essential regulators of mitotic entry and progression, whereas aurora-C function is primarily restricted to male meiosis during spermatogenesis (5) (6) (7) (8) (9) (10) . Aurora-A can function as an oncogene and is amplified in a subset of human tumors. Aurora-A and -B expression is frequently elevated in human cancers and is associated with advanced clinical staging (11) .
The mitotic checkpoint, also referred to as the spindle assembly checkpoint (SAC), is a surveillance mechanism responsible for controlling proper alignment, microtubule-kinetochore attachments, and segregation of duplicated chromosomes (12) . In tumor cells, genetic depletion or pharmacological inhibition of aurora-A results in abnormal spindle formation and SAC activation. In constrast, depletion or inhibition of aurora-B inactivates the SAC, resulting in aborted cell division without a mitotic arrest. Importantly, dual suppression of aurora-A and -B phenocopies the effects of inhibiting aurora-B alone (13, 14) . The silencing of the SAC leads to an accumulation of tumor cells that contain 4N DNA content in the G 1 -phase of the cell cycle. Continued suppression of aurora-B activity leads to further rounds of genome replication without division, a process referred to as endoreduplication, which ultimately results in tumor cell death (15, 16) . This mechanism of action is distinct from that of microtubule-binding antimitotic drugs (e.g. taxanes, vinca alkaloids, and epothilones) in that death of Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research 6 specificity of AMG 900 across the kinome, a panel of 26 kinases was screened, and only p38α and TYK2 enzymes were inhibited (> 50%) at concentrations less than 500 nmol/L (Fig. 1A) . Further screening was performed against a panel of 353 distinct kinases using an ATP-site dependent competition binding assay (28) . AMG 900 exhibited low nanomolar binding affinity for aurora kinases as well as interactions (
nmol/L) with DDR1, DDR2, and LTK receptor tyrosine kinases (Fig. 1A) .
To investigate the inhibition of aurora kinase activity in cells by AMG 900, the levels of phosphorylated aurora-A Thr Figure 1D shows a representative DMSO-treated cell entering and exiting mitosis to yield two daughter cells. In contrast, a representative AMG 900-treated cell entering mitosis failed to properly congress chromosomes to the metaphase plate, which subsequently resulted in aborted cell division (bottom panel of Fig. 1D ). These data demonstrate that AMG 900 does not induce a prolonged cell arrest in mitosis, consistent with inhibition of aurora-B and SAC silencing.
Effects of AMG 900 on proliferating cells are consistent with inhibition of aurora-B activity.
Suppression of aurora-B activity in mitosis is known to induce polyploidy in tumor cells as a consequence of cytokinesis failure. To confirm this, we first determined the concentration of AMG 900 that completely suppressed p-histone H3 in HCT116 cells ( Fig. 2A) . Treatment of HCT116 cells with 50 nmol/L of AMG 900 for 48 hours resulted in polyploidy and suppressed the formation of colonies after cell replating ( S2B ). Both of the HCT116 cell lines were equally sensitive to paclitaxel and were negative for P-gp and BCRP expression ( Supplementary Fig. S2C ). Interestingly, the HCT116 variant subline harbors a missense mutation in one allele of the aurora-B gene (TGG  TTG; W221L), whereas no mutations were detected in the aurora-A and -C genes. These results suggest that AMG 900 maintains activity in tumor cells carrying a heterozygous mutation in aurora-B that may be responsible for resistance to AZD1152. Somatic point mutations at the analogous residue adjacent to the invariant DFG motif have been found in epidermal growth factor receptor and BRAF genes (L858R and L596R, respectively) in primary human tumors (36, 37) . Studies are underway to more fully characterize the biological effects of this aurora-B mutation. (Fig. 4D ). This continuous schedule with lower doses of AMG 900 resulted in significant tumor growth inhibition when compared with the vehicletreated control group (2.25 mg/kg; 51% inhibition, P = 0.0019) and 3 mg/kg; 74% inhibition, P < 0.0001).
Daily dosing with AMG 900 was well-tolerated with no adverse effect on body weight ( Supplementary Fig.   S4B ), although a decrease in neutrophil counts was observed at the end of the study (data not shown).
The effect of AMG 900 on tumor growth was further evaluated in a panel of human xenografts from five different tumor types (breast, colon, lung, pancreatic, and uterine), including three MDR xenograft models. Mice bearing established tumors were orally administered AMG 900 at 15 mg/kg b.i.d.
for two consecutive days per week or at 3 mg/kg b.i.d. every day for the duration of the study. As shown in Figure 5A , AMG 900 exhibited significant antitumor activity in all nine xenograft models tested (50 to 
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97% tumor growth inhibition (TGI) compared with the vehicle-treated control group, *P < 0.005, **P < 0.0005). Importantly, AMG 900 was active in the MES-SA-Dx5 (84% TGI, P < 0.0001) and NCI-H460-PTX (66% TGI, P < 0.0001) xenograft models that were resistant to either docetaxel or paclitaxel administered at their respective maximum tolerated doses ( Fig. 5B and 5C ). Together, these in vivo data provide evidence that AMG 900 inhibits the activity of aurora-B in HCT116 tumors and suppresses the growth of multiple xenografts that represent diverse tumor types. Notably, our data indicate that AMG 900 has the potential to treat tumors resistant to standard-of-care antimitotic drugs.
Since inhibition of aurora-B activity is known to cause myelosuppression (11, 25) , studies were performed to examine the effects of PEGylated-granulocyte colony-stimulating factor (SD/02) administration on AMG 900-induced neutropenia. Mice were treated with AMG 900 at 15 mg/kg b.i.d for two consecutive days alone or with SD/02 at 1 mg/kg one day subsequent to the first day of AMG 900 treatment. Administration of AMG 900 alone showed a marked reduction in neutrophils by day 4 after treatment followed by a full recovery of neutrophils by day 8. Mice administered SD/02 one day after the initiation of AMG 900 treatment showed a significant decrease in the duration of neutropenia compared to AMG 900 treatment alone (days 6, 7, and 8 (P < 0.0001) and day 11 (P < 0.0018), Supplementary Fig.   S5 ).
Discussion
Targeting the structural components of the mitotic machinery is a proven intervention strategy in the treatment of cancer. Microtubule-binding agents such as the taxanes and vinca alkaloids are highly active against a variety of human cancer types, although multidrug resistance and peripheral neuropathy remain persistent problems. Consequently, there is a need for novel antimitotic drugs that target nonmicrotubule proteins such as the mitotic kinases (38, 39) . In the past decade, aurora-A and -B have gained prominence as essential regulators of somatic cell division and represent promising mitotic targets for anticancer therapy.
In this report, we have described the preclinical activities of AMG 900, a novel potent and highly After the DMSO-treated cells reached confluence, the cells were stained with crystal violet and imaged (duplicate wells). Table 1 . AMG 900 exhibits uniform potency in human tumor cell lines expressing P-gp and BCRP resistant to one or more aurora kinase inhibitors 
